Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Total Long-Term Assets: ₹602 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MADHAVBAUG Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
77 GF Score
Price ₹173.00
GF Value ₹228.23
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Vaidyane Ayurved Laboratories Total Long-Term Assets?

Vaidyane Ayurved Laboratories NSE:MADHAVBAUG -3.35% 77 Total Long-Term Assets is ₹602 Mil as of Mar. 2026. GuruFocus rates NSE:MADHAVBAUG with a GF Score™ of 77/100 and a GF Value™ of ₹228.23 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Vaidyane Ayurved Laboratories's Total Long-Term Assets for the quarter that ended in Mar. 2026 was ₹602 Mil.

Vaidyane Ayurved Laboratories Total Long-Term Assets Related Terms

Vaidyane Ayurved Laboratories Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Vaidyane Ayurved Laboratories's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaidyane Ayurved Laboratories Total Long-Term Assets Chart

Vaidyane Ayurved Laboratories Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial 244.81 270.99 383.63 464.25 601.98

Vaidyane Ayurved Laboratories Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 383.63 396.44 464.25 529.85 601.98
NSE:MADHAVBAUG
77GF Score
Vaidya Sane Ayurved Laboratories Ltd NSE:MADHAVBAUG
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaidyane Ayurved Laboratories Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ₹602 Mil mean?
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a Total Long-Term Assets of ₹602 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Vaidyane Ayurved Laboratories and its competitors.
Is Vaidyane Ayurved Laboratories' Total Long-Term Assets too high?
Vaidyane Ayurved Laboratories' current Total Long-Term Assets is ₹602 Mil. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' Total Long-Term Assets compare to ZTS?
Vaidyane Ayurved Laboratories' Total Long-Term Assets of ₹602 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Vaidyane Ayurved Laboratories and its competitors. Vaidyane Ayurved Laboratories's current Total Long-Term Assets is ₹602 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹228.23, compared to a current price of ₹173.00 — trading 24.2% below its estimated fair value. The current Total Long-Term Assets is ₹602 Mil. Vaidyane Ayurved Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current Total Long-Term Assets is ₹602 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?

Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued. The current stock price of ₹173.00 is trading 24.2% below its estimated GF Value™ of ₹228.23. GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:MADHAVBAUG:

  • Total Long-Term Assets: ₹602 Mil
  • GF Value™: ₹228.23 vs. price of ₹173.00 (24.2% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaidyane Ayurved Laboratories Business Description

Address 201B, Bhoomi Velocity, Above ICICI Bank, Road No. 23, Wagle Estate, Thane (West), Thane, MH, IND, 400604
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
77GF Score

Get the complete analysis for NSE:MADHAVBAUG

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹173.00
Price
₹228.23
GF Value